Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Herrick

Interventional Pain Medicine Montgomery, AL Medical Doctor

NPI 1205982998 CMS profile 326578

2065 E South Blvd, 401, Montgomery, AL 36116

Open in the dashboard

General payments

$9,417

425 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Herrick of Montgomery, AL is reported in the CMS Open Payments database as having received $9,417 across 425 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,236 73
2024 General $1,634 61
2023 General $934 63
2022 General $1,434 53
2021 General $1,790 76
2020 General $1,528 59
2019 General $859 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Herrick
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to David Herrick were reported at $1,236. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year David Herrick Interventional Pain Medicine median Middle half National median
2019 $859 $684 $216–$2,079 $163
2020 $1,528 $382 $122–$1,109 $114
2021 $1,790 $552 $167–$1,554 $132
2022 $1,434 $605 $187–$1,924 $149
2023 $934 $671 $195–$1,915 $160
2024 $1,634 $684 $206–$1,837 $164
2025 $1,236 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,883 249 payments
  2. Boston Scientific Corporation $1,346 72 payments
  3. Collegium Pharmaceutical, Inc. $494 30 payments
  4. Forte Bio-Pharma LLC $288 18 payments
  5. MML US, Inc. $259 1 payment
  6. Biodelivery Sciences International, Inc. $137 7 payments
  7. Curonix LLC $98 1 payment
  8. SI-BONE, Inc. $92 1 payment
  9. Scilex Pharmaceuticals Inc. $77 5 payments
  10. Stimwave Technologies Incorporated $72 2 payments
  11. Other $671 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,040 423 payments
  2. Travel and Lodging $376 2 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM $2,095 87 payments
  2. Proclaim Family of SCS IPGs $1,489 52 payments
  3. Proclaim IPG $946 45 payments
  4. ETERNA $459 21 payments
  5. Infinion 16 $431 35 payments
  6. XTAMPZA $350 21 payments
  7. ARTISAN $293 7 payments
  8. PROLATE Pain $288 18 payments
  9. PROLATE Pain $288 18 payments
  10. PROLATE Pain $288 18 payments
  11. Other $3,372 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

24,647

Median for Anesthesiology: 322

Drug cost

$815,080

Median for Anesthesiology: $8,738

Branded share of claims

45.2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 5,737 $105,219
Buprenorphine Generic 353 $102,900
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 3,849 $96,025
Belbuca Buprenorphine Hcl Brand 124 $82,685
Oxycontin Oxycodone Hcl Brand 130 $74,100
Xtampza Er Oxycodone Myristate Brand 98 $58,131
Movantik Naloxegol Oxalate Brand 90 $36,650
Gabapentin Generic 3,115 $33,741
Nucynta Tapentadol Hcl Brand 39 $26,172
Pregabalin Generic 898 $23,325

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$677,018

Of which drugs: $18,754

Medicare patients

834

Average age 72

Services billed

68,719

504 women, 330 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 33%
Ischemic heart disease 32%
Depression 25%
Chronic kidney disease 24%
COPD 21%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 390 53,362 $5,331
Injection, methylprednisolone acetate, 80 mg J1040 Office 168 193 $1,385
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 191 4,543 $393
Injection, midazolam hydrochloride, per 1 mg J2250 Office 352 2,087 $220
Injection, ketorolac tromethamine, per 15 mg J1885 Office 35 195 $90

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $36
$36 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $22
$22 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $21
$21 124 —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $18
$18 98 —
NALOCET
  • Forte Bio-Pharma LLC $9
$9 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

425 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record